JP Morgan banker faces another bitter pill as AbbVie mulls $50bn reverse

AbbVie may decide to scrap its planned $56.1 billion deal for UK drugmaker Shire after a US crackdown on so-called inversion deals

One of JP Morgan’s top investment bankers in London is facing fresh multibillion-dollar disappointment as his client decides whether to pull the plug on a $50 billion-plus deal.

Laurence Hollingworth, JP Morgan's head of industry coverage for corporates in Europe, the Middle East and Africa, is one of three London-based bankers advising pharmaceuticals giant AbbVie on its proposed $56.1 billion takeover of the UK drugmaker Shire.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump